NEW YORK (GenomeWeb News) – Exonhit and BGI today announced they have completed a project to expand Exonhit's SpliceArray platform to an additional "strategic preclinical animal model species."
BGI's next-generation sequencing technology was combined with SpliceArray resulting in a "new powerful combination [that] will facilitate the rapid discovery, development, and commercialization of the most relevant therapeutics, biomarkers, and molecular diagnostics," Matthew Pando, executive vice president of therapeutics at Exonhit, said in a statement.
The goal of the project, whose terms have not been disclosed, is to shed light on gene deregulation and to develop biomarkers and molecular diagnostics for complex diseases, Exonhit said.
SpliceArray is a microarray-based platform that incorporates a specific probe configuration and is designed to monitor each isoform of an RNA splicing event, Paris-based Exonhit said on its website. The Human Genome-wide SpliceArray monitors known and predicted RNA-splicing events in almost 21,000 genes.